Related Experiment Video
Updated: Jun 9, 2025
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib
Samuel Akaakole Mensah1, Syed Ahmad2, Waleed Alruwaili2
1Department of Medicine, West Virginia University, Morgantown, West Virginia, USA sakaakole@gmail.com.
Objectives:
There have been cases of cardiotoxicity induced by osimertinib in patients with non-small-cell lung cancer (NSCLC). However, limited data exist for a comprehensive cardiotoxicity profile analysis for osimertinib use in NSCLC patients. The aim of this study was to report the entire profile of cardiotoxicities after the initiation of osimertinib in consecutive patients with epidermal growth factor receptor (EGFR) mutation at a single health system.
Methods:
The data were retrospectively collected from electronic medical records for all patients who were started on osimertinib for NSCLC at West Virginia University Health System. Prevalence of heart failure (HF), atrial fibrillation, and prolonged QT before and after starting osimertinib were calculated.
Results:
This study had 116 participants and the median age was 72 years. The frequency of each new cardiotoxicity was between 6% and 9%, and the overall percentage of patients who had developed any of the four cardiotoxicities while on osimertinib was 19.9%. The median time of follow-up was 477 days and the median time on osimertinib for all patients was 390 days. The strongest risk factor in predicting a new onset cardiac event was hypertension with a hazard ratio (HR) of 6.35 (confidence interval (CI) 1.48 to 27.23, p=0.013) and HR 5.36 (CI 1.23 to 23.39, p=0.025) in univariate and multivariate analysis respectively.
Conclusion:
Osimertinib appears to be associated with an increase in cardiac abnormalities. Given the association between this medication exposure and the observed cardiac toxicities, use of osimertinib may entail closer cardiac monitoring of electrocardiogram (ECG) and echocardiogram abnormalities.
Insights
Osimertinib can cause cardiac issues in non-small cell lung cancer (NSCLC) patients, with 19.9% experiencing cardiotoxicity. Hypertension is a significant risk factor, suggesting closer cardiac monitoring during EGFR-mutated NSCLC treatment.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Osimertinib is a targeted therapy for EGFR-mutated non-small cell lung cancer (NSCLC).
- Cardiotoxicity is a known but not fully characterized side effect of osimertinib.
- Limited comprehensive data exist on the cardiac safety profile of osimertinib in NSCLC patients.
Purpose of the Study:
- To comprehensively analyze the cardiotoxicity profile associated with osimertinib initiation in NSCLC patients.
- To determine the prevalence of specific cardiac abnormalities, including heart failure, atrial fibrillation, and QT prolongation.
- To identify potential risk factors for osimertinib-induced cardiotoxicity.
Main Methods:
- Retrospective analysis of electronic medical records from West Virginia University Health System.
- Inclusion of consecutive NSCLC patients initiated on osimertinib.
- Calculation of prevalence for heart failure, atrial fibrillation, and prolonged QT before and after osimertinib initiation.
Main Results:
- 116 patients with a median age of 72 were included.
- 19.9% of patients developed at least one new cardiotoxicity.
- Hypertension was identified as the strongest predictor of new cardiac events (HR 6.35 univariate, HR 5.36 multivariate).
Conclusions:
- Osimertinib use is associated with an increased incidence of cardiac abnormalities in NSCLC patients.
- The findings suggest a need for enhanced cardiac monitoring, including ECG and echocardiograms.
- Patients with hypertension may require particularly close surveillance for cardiotoxicity during osimertinib treatment.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...